1.27
+0.01(+0.79%)
Currency In USD
| Previous Close | 1.26 |
| Open | 1.25 |
| Day High | 1.27 |
| Day Low | 1.25 |
| 52-Week High | 22.9 |
| 52-Week Low | 1.1 |
| Volume | 55,244 |
| Average Volume | 99,662 |
| Market Cap | 9.57M |
| PE | -0.21 |
| EPS | -6.1 |
| Moving Average 50 Days | 1.43 |
| Moving Average 200 Days | 5.03 |
| Change | 0.01 |
If you invested $1000 in BioVie Inc. (BIVI) since IPO date, it would be worth $1.27 as of January 14, 2026 at a share price of $1.27. Whereas If you bought $1000 worth of BioVie Inc. (BIVI) shares 5 years ago, it would be worth $0.42 as of January 14, 2026 at a share price of $1.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
- Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone - - Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 - CARSON CITY, Nev., Jan. 08, 2026 (GLOBE NEWSWIRE) -- B
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9
GlobeNewswire Inc.
Nov 19, 2025 1:00 PM GMT
CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investo
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
GlobeNewswire Inc.
Sep 26, 2025 12:00 PM GMT
CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an investor webin